恩格列净在心力衰竭患者中跨越不同肾脏风险类别的疗效
本研究 pooled 分析 EMPEROR-Reduced 和 EMPEROR-Preserved 试验的 9,718 例心力衰竭患者,按 KDIGO 类别分组。恩格列净降低心血管死亡或心衰住院风险在各 KDIGO 类别中相似(P trend=0.30)。恩格列净延缓 eGFR 下降速率,但其幅度取决于 eGFR 斜率计算方法。
要点
- 恩格列净对主要心衰事件的获益不受 KDIGO 肾脏风险类别影响。
- 恩格列净在各 KDIGO 类别中降低心血管死亡或心衰住院风险相似。
- 恩格列净延缓 eGFR 下降,但效应幅度取决于斜率计算方法。
核心结论
- 恩格列净对主要心衰事件的获益不受 KDIGO 肾脏风险类别影响。
- 恩格列净对肾脏效应的幅度取决于计算 eGFR 斜率的方法。
研究设计与样本
- EMPEROR-Reduced 和 EMPEROR-Preserved 试验的 pooled 分析,共纳入 9,718 例患者。
- 按 KDIGO 类别基于 eGFR 和尿白蛋白/肌酐比值分为低、中、高、极高风险组,分别占 32.0%、29.1%、21.9%、17.0%。
主要发现
- 在安慰剂组,较高风险类别患者 eGFR 下降速率较慢,但复合肾脏事件风险较高。
- 恩格列净降低心血管死亡或心衰住院风险在各 KDIGO 类别中相似:低风险 HR 0.81(95% CI 0.66-1.01),中风险 HR 0.63(95% CI 0.52-0.76),高风险 HR 0.82(95% CI 0.68-0.98),极高风险 HR 0.84(95% CI 0.71-1.01),P trend=0.30。
- 恩格列净延缓 eGFR 下降速率,无论采用 chronic slope、total slope 还是 unconfounded slope 估算。
- 与 unconfounded slope 相比,对 chronic slope 的效应幅度更大,对 total slope 的效应幅度更小。
- 在 EMPEROR-Reduced 中,最低风险患者 eGFR 斜率获益最大;此模式在 EMPEROR-Preserved 中未观察到。
临床怎么用
- 恩格列净可考虑用于心力衰竭患者,无论其 KDIGO 肾脏风险类别。
- 评估恩格列净肾脏效应时需注意 eGFR 斜率计算方法的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Empagliflozin reduces the risk of major heart failure outcomes in heart failure with reduced or preserved ejection fraction. OBJECTIVES: The goal of this study was to evaluate the effect of empagliflozin across the spectrum of chronic kidney disease in a pooled analysis of EMPEROR-Reduced and EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced or Preserved Ejection Fraction, respectively). METHODS: A total of 9,718 patients were grouped into Kidney Disease Improving Global Outcomes (KDIGO) categories based on estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio into low-, moderate-, high-, and very-high-risk categories, comprising 32.0%, 29.1%, 21.9%, and 17.0% of the participants, respectively. RESULTS: In the placebo arm, when compared with lower risk categories, patients at higher risk experienced a slower rate of decline in eGFR, but a higher risk of a composite kidney event. Empagliflozin reduced the risk of cardiovascular death or heart failure hospitalizations similarly in all KDIGO categories (HR: 0.81; 95% CI: 0.66-1.01 for low-; HR: 0.63; 95% CI: 0.52-0.76 for moderate-; HR: 0.82; 95% CI: 0.68-0.98 for high-; and HR: 0.84; 95% CI: 0.71-1.01 for very-high-risk groups; P trend = 0.30). Empagliflozin reduced the rate of decline in eGFR whether it was estimated by chronic slope, total slope, or unconfounded slope. When compared with the unconfounded slope, the magnitude of the effect on chronic slope was larger, and the effect on total slope was smaller. In EMPEROR-Reduced, patients at lowest risk experienced the largest effect of empagliflozin on eGFR slope; this pattern was not observed in EMPEROR-Preserved. CONCLUSIONS: The benefit of empagliflozin on major heart failure events was not influenced by KDIGO categories. The magnitude of the renal effects of the drug depended on the approach used to calculate eGFR slopes.
引用
- Butler, Packer, Siddiqi, et al. Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories. J Am Coll Cardiol. 2023. PMID: 37164523. doi:10.1016/j.jacc.2023.03.390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。